Amid remarkable strides in treating rare diseases and the pressing challenges posed by ageing populations, healthcare investment landscapes are being reshaped. Opportunities abound for investors focused on long-term trends, with...
A biotech titan, renowned for its mRNA innovation, might just be undervalued at a price nearly equivalent to its cash reserves. With $2 billion in COVID-19 vaccine revenues and over...
The biotech sector is in turmoil after the nomination of a controversial U.S. health official, raising fears of disrupted vaccine development and regulatory changes. Share prices for companies like Moderna...
In the evolving landscape of biotech regulation, whispers of change at the FDA signal a potential renaissance. Recent leadership shifts hint at a more innovation-friendly approach, potentially expediting approvals for...
Vertex Pharmaceuticals is quietly establishing itself as a powerhouse, generating over $10 billion in annual revenue. With trailblazing innovations like the CRISPR-based Casgevy and non-opioid Journavx, Vertex is reshaping the...
As we find ourselves in mid-2025, biotech stocks are echoing the tempered days of 2018, sitting at around 50% below their 2021 highs. This recalibration raises a vital question: are...
Discover Regeneron Pharmaceuticals' enigmatic valuation, where a robust innovation pipeline and proprietary technologies are seemingly overlooked by the market. Explore how this biotech titan's untapped potential, from its VelociSuite technology...
Regeneron Pharmaceuticals, a biotech behemoth, has seen a dramatic 60% drop from its peak valuation of $120 billion, presenting a tantalising dilemma for investors: disaster or opportunity? With strong fundamentals...
Biotech, traditionally a powerhouse of innovation, has been stuck in an unexpected rut for nearly a decade, lagging behind broader market progress. Despite groundbreaking advancements in gene editing and personalised...
A remarkable 23% of biotech companies are now trading with negative enterprise values, signalling profound investor scepticism. This condition suggests a sector-wide crisis of confidence, with implications ranging from M&A...
